

Case study

Removing translation bottlenecks with Al

How Medable and Lionbridge streamlined global study builds and cut translation timelines by 43% using new Al tools.

Study selection and approach

Traditionally, translations and language migration create significant bottlenecks on the path to trial study go-live. The process is traditionally manual, linear, and resource intensive. To address these challenges, Medable partnered with Lionbridge, a leading translation services company to compare the status quo translation process against an Al-enabled approach powered by both companies' proprietary new Al tools.

The teams selected a study originally built with standard methods and rebuilt it using their new Al-enabled platforms for a side-by-side comparison.

Al solutions used

Study parameters

Therapeutic Area Medable Studio

Oncolytic Immunotherapy

Locales

8 total including English (UK), Czech, French (France), German (Germany), Greek, Polish, Spanish (Spain), Spanish (US) Medable's Al-enhanced interface that enables rapid study build, testing, and deployment.

Lionbridge Aurora Clinical Outcomes

An Al-driven proprietary technology platform supporting global eCOA migration process while maintaining high quality and regulatory compliance.

Outcomes + impact

The use of two AI solutions led to major improvements in the translation and migration processes. Not only was the overall project timeline shortened, but day-to-day operations became markedly more efficient. Tasks that traditionally required extensive back-and-forth communication, manual coordination, and multiple review cycles were streamlined through automation and intelligent task coordination.

Medable Studio drove key efficiencies in the trial build, which stemmed from a significant reduction in the time dedicated to creating and reviewing screenshots from translated documents. Beyond these time savings, the team saw substantial resource optimization. This process, which previously engaged as many as three teams across numerous systems, has been streamlined to involve only one to two teams and a single system.

Lionbridge's Aurora Clinical Outcome automations stemmed from the ability to batch multiple languages for simultaneous processing, eliminating the need for a step-by-step, language-by-language approach.

The streamlined translation and migration process automated key localization steps and validated migrated content against original paper versions without compromising accuracy or compliance.

Medable's Al-powered approach and Lionbridge's automations enabled linguistic migrations to begin earlier in the process, breaking the traditional linear dependency on completed builds and UAT.


Automation reduced manual effort and minimized human error, while improved workflow visibility ensured alignment between build and translation teams.

These cumulative outcome enhancements translated into faster project completion, reduced resource requirements, and more agile collaboration across teams. Most importantly, they removed key bottlenecks in the translation and language migration process. This ultimately enabled a smoother, more predictable path to study go-live.

The result

43%

Reduction in overall translation timelines and significantly fewer administrative steps, demonstrating how modern AI tools can reimagine often overlooked translation bottlenecks on the path to study go live.



Medable and Lionbridge's Al solutions resulted in:

43%

fewer business days to complete all languages

55%

shorter timeline for screenshot review rounds with Medable Studio

54%

reduction in emails back and forth between Lionbridge and Medable

Increased efficiency through reduction of teams and systems, specifically on the Medable side reduced teams from 2–3 teams and multiple platforms to 1–2 teams and one platform.

Impact for sponsors and customers

This case study showcases how implementing Al into the translation process can deliver substantial time savings, reducing resources, and accelerating clinical trial readiness.

Moving forward, sponsors and partners can expect:

- → Scalable and repeatable efficiencies in global studies
- Earlier trial launches and enhanced competitive advantage
- Maximized resource allocation due to fewer communication touchpoints

This Al-powered approach sets a new benchmark in clinical trial operations, demonstrating the clear advantage of proactively addressing translation bottlenecks through Al innovation.

"At Medable, we're committed to removing operational bottlenecks that slow down clinical development. This partnership with Lionbridge demonstrated the tangible value of Al-powered platforms in accelerating global trial timelines. By enabling parallel workflows and automating critical tasks, we reduced translation time by 43%–a breakthrough that sets a new benchmark for clinical trial efficiency."

Alison Holland, Chief Customer Officer, Medable

Since the completion date of the rebuild, Medable's Al translation capabilities have evolved. Our current Al-driven translation further reduces the need for multiple rounds of review and revision and significantly decreases the risk of transcription errors, especially when a validated paper version of the translated text is required.